Page 441 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(21) Zarin DA, Tse T. Trust but Verify: Trial Registration and Deter-
mining Fidelity to the Protocol. Ann Intern Med. 2013;159(1):65–67.

(22) Rosenthal R, Dwan K. Comparison of randomized controlled trial
registry entries and content of reports in surgery journals. Ann Surg. 2013
Jun;257(6):1007–15.

(23) Zetterqvist AV, Mulinari S (2013) Misleading Advertising for
Antidepressants in Sweden: A Failure of Pharmaceutical Industry Self-
Regulation. PLoS ONE 8(5): e62609. doi:10.1371/journal.pone.0062609.

(24) Mintzes B, Lexchin J, Sutherland JM, Beaulieu M-D, Wilkes MS,
Durrieu G, et al. Pharmaceutical Sales Representatives and Patient Safety:
A Comparative Prospective Study of Information Quality in Canada, France
and the United States. J Gen Intern Med. 2013 Apr 5.

(25) http://dailycaller.com/2013/04/27/critics-see-conflict-ofintere
stas-obama-admin-advises-doctors-on-prescriptions/.

(26) http://www.propublica.org/article/pay-to-prescribe-twodoze
ndoctors-named-in-novartis-kickback-case.

(27) Bosch X, Hernández C; Pericas JM, Doti P. Ghostwriting Policies in
High-Impact Biomedical Journals: A Cross-Sectional Study. JAMA Intern
Med. 2013;173(10):920-921.

(28) Nancarrow, CM. Editorial Policies to Ensure Honesty and Trans-
parency: Comment on “Ghostwriting Policies in High-Impact Biomedical
Journals: A Cross-Sectional Study”. JAMA Intern Med. 2013;173(10):921-
922.

(29) Persaud N. Questionable content of an industry-supported
medical school lecture series: a case study. J Med Ethics. doi:10.1136/
medethics-2013-101343.

(30) India’s poor duped into clinical drug trials. Economic Times, 7th
July 2013.

441